Sanofi, a big French drug company, has a new CEO. Paul Hudson is stepping down after six years. During his time, Sanofi changed a lot, and their medicine Dupixent became one of the world’s top sellers. Belén Garijo, currently the CEO of Merck KGaA, will take over. She starts her new role at Sanofi on February 17. Until then, Olivier Charmeil will be the temporary CEO. Sanofi believes Garijo will help the company grow and innovate more. She worked at Sanofi before and has a lot of experience in the industry. The company’s shares dropped a bit when this news came out, but Sanofi is confident in Garijo’s abilities. Some experts are not sure about this change, but others think Garijo did a good job at Merck KGaA. Under Hudson, Sanofi focused on certain types of medicines and made Dupixent a success. However, they faced some setbacks and need to keep growing. Garijo’s appointment will be voted on at the next shareholder meeting in April. Sanofi is also changing their rules to allow CEOs to be older than 65.